AlgenScribe
Latest round
- Seed
Last raised
- Nov 2025
Total raised
- $0.6M
Investors
- 2
About AlgenScribe
Based in France, AlgenScribe SAS specializes in genome editing solutions, focusing on developing advanced technologies to enhance genetic research and therapeutic applications. AlgenScribe SAS, founded in 2022, co-founded by CEO, Frédéric Zampatti, Dr. Isabelle Malcuit and Dr. Alexander Sorokin, operates out of Nice, France. The company is dedicated to genome editing innovations and has executed a total of one deal since its inception.net. The company helps a variety of clients, from individual entrepreneurs to established businesses, secure unique web addresses essential for branding and digital identity. Beyond domain registration, AlgenScribe offers insights into WHOIS data, enhancing clients' understanding of public registration details and domain ownership implications. The products cater to markets in North America, Europe, and Asia, addressing the needs of both startups and established firms seeking online branding solutions. AlgenScribe's revenue model is built on domain registration fees and related services for online presence management. Customers engage in transactions directly with the company, paying for domain registrations and renewals via subscription models. Fees vary by domain name extensions and additional services like WHOIS privacy protection. Clients may choose annual or multi-year registration plans, which provide cost savings while ensuring ownership of their domains. Specific pricing details are not publicly disclosed, but the revenue model is designed to serve a wide range of customers, from individuals to larger enterprises requiring multiple registrations. which will be allocated to further develop its genome-editing platform, including ex-vivo projects and early disease model studies. The company has plans to expand its market reach into new geographic areas, although specific regions and timelines are not mentioned.
Who invested in AlgenScribe
2 investors across 1 round
See all investors in AlgenScribe
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Nov 18, 2025
Amount
$0.6M
Investors
Questions about AlgenScribe
Who invested in AlgenScribe?
AlgenScribe has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AlgenScribe raised?
AlgenScribe has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AlgenScribe last raise money?
AlgenScribe's most recent round on record is a Seed, in Nov 2025.
What does AlgenScribe do?
Based in France, AlgenScribe SAS specializes in genome editing solutions, focusing on developing advanced technologies to enhance genetic research and therapeutic applications.
Where is AlgenScribe headquartered?
AlgenScribe is headquartered in Nice, France.
Which VCs invest in companies like AlgenScribe?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at AlgenScribe's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like AlgenScribe? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.